Intracellular functions of APOL1 in the kidney

APOL1 在肾脏中的细胞内功能

基本信息

  • 批准号:
    10383979
  • 负责人:
  • 金额:
    $ 56.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-23 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Chronic kidney disease (CKD) in African Americans is one of the largest racial health disparities in the United States. The cause for the increased risk has been attributed to recessive inheritance of allelic variants in the gene for apolipoprotein L1 (APOL1). These APOL1 variants, known as G1 and G2, do not cause CKD on their own, but CKD is caused by a combination of the inherited genetic risk plus exposure to a triggering environmental stressor (a gene-environment interaction). Despite the association of CKD risk with APOL1 variants more than ten years ago, the biological function of APOL1 in the kidney and the mechanism of pathogenesis in the setting of a disease stressor remain unclear. Our long-term goal is to understand the genetics and biochemical mechanism of CKD in African Americans caused by these APOL1 polymorphisms. To accomplish this goal, we are studying HIV-associated nephropathy (HIVAN), the CKD most strongly associated APOL1 variants, and the only CKD where the environmental stressor is known (HIV infection). HIVAN is an ideal disease model to dissect biochemical pathways and cellular events intersected by APOL1 function, viral infection, and CKD. Our recent studies have demonstrated, for the first time, a function for the common APOL1 allele, known as G0, in providing protection against podocyte losses in HIVAN. Since APOL1 risk is a recessively inherited trait, this suggests CKD may be caused, in part, by a loss-of-function process (i.e. absence of G0). In new preliminary data, G0 appears to associate with Toll-like receptors (TLRs) in intracellular vesicles containing HIV and facilitate signaling events initiated by interferon regulatory factor (IRF)-3, and these processes were absent with the APOL1 risk variants. Methods will use established in vitro HIV infection of human podocyte cell lines, in vivo models of HIVAN and BAC-APOL1 transgenic mice that replicate endogenous human APOL1 expression. Aims will examine both initial response to HIV infection in podocytes, and long-term in vivo studies of intercrosses between the HIVAN and BAC-APOL1 transgenic mice evaluating effects on renal function and pathology. These studies also will establish temporal and magnitude of stressor-induced APOL1 expression, the mechanism of the altered innate immune activation through TLRs to IRF-3/7 signaling, and effect on podocyte phenotype (survival and cell adhesion). The dominance of the G0 protective effect over the risk variant dysfunction will be tested in podocytes and mouse models co-expressing G0 and the risk variants. These studies should advance our understanding of gain- versus loss-of-function mechanism associated with the recessive inheritance of APOL1 risk alleles, and the necessity of induced APOL1 expression to drive stress responses. Determining the contribution of G0 function versus risk variant dysfunction will have important clinical impact on further therapy design, as it will establish whether replacement of G0 or suppression of the risk variants would be the more effective strategy.
摘要 非裔美国人的慢性肾病(CKD)是美国最大的种族健康差距之一 各州。风险增加的原因被归因于等位基因变异的隐性遗传 载脂蛋白L1基因(APOL1)。这些被称为G1和G2的APOL1变体不会在其 自己的,但慢性肾脏病是由遗传遗传风险和暴露在触发环境中的组合引起的 应激源(一种基因-环境相互作用)。尽管CKD风险与APOL1变异体的关联超过 10年前,APOL1在肾脏中的生物学功能及其发病机制 疾病应激源的作用尚不清楚。我们的长期目标是了解遗传学和生物化学 这些APOL1基因多态性导致非裔美国人慢性肾脏病的机制。为了实现这一目标,我们 正在研究艾滋病毒相关性肾病(HIVAN),这是CKD相关性最强的APOL1变体,以及 只有在已知环境应激源(艾滋病毒感染)的情况下,CKD才会发生。HIVAN是一种理想的解剖疾病模型 与APOL1功能、病毒感染和慢性肾脏病交叉的生化途径和细胞事件。我们最近 研究首次证明了常见的APOL1等位基因,即G0,在提供 在HIVAN中保护足细胞免受损失。由于APOL1风险是一种隐性遗传特征,这表明 CKD可能部分是由功能丧失过程(即G0缺失)引起的。在新的初步数据中,G0 似乎与含有HIV的细胞内囊泡中的Toll样受体(TLRs)有关,并促进信号转导 由干扰素调节因子(IRF)-3启动的事件,这些过程不存在APOL1风险 变种。方法将建立的HIV体外感染人足细胞系、体内HIVAN模型 以及复制内源性人APOL1表达的BAC-APOL1转基因小鼠。AIMS将审查这两个问题 足细胞对HIV感染的初步反应,以及HIVAN之间杂交的长期体内研究 并评价BAC-APOL1转基因小鼠对肾功能和病理的影响。这些研究也将 建立应激源诱导的APOL1表达的时间和幅度,以及先天改变的机制 通过TLRs对IRF-3/7信号的免疫激活及其对足细胞表型(存活和细胞)的影响 附着力)。G0保护作用对风险变异功能障碍的优势将在足细胞中进行测试 以及共同表达G0和风险变体的小鼠模型。这些研究应该会促进我们对 与APOL1风险等位基因隐性遗传相关的获得和功能丧失机制,以及 诱导APOL1表达以驱动应激反应的必要性。确定G0的贡献 功能与风险变异功能障碍将对进一步的治疗设计产生重要的临床影响,正如它将 确定替换G0或抑制风险变量是否为更有效的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leslie A Bruggeman其他文献

Leslie A Bruggeman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leslie A Bruggeman', 18)}}的其他基金

Mechanisms of Kidney Diseases Associated With APOL1 Variation
APOL1 变异相关肾脏疾病的机制
  • 批准号:
    10607630
  • 财政年份:
    2023
  • 资助金额:
    $ 56.49万
  • 项目类别:
Intracellular functions of APOL1 in the kidney
APOL1 在肾脏中的细胞内功能
  • 批准号:
    10493392
  • 财政年份:
    2021
  • 资助金额:
    $ 56.49万
  • 项目类别:
Intracellular functions of APOL1 in the kidney
APOL1 在肾脏中的细胞内功能
  • 批准号:
    10666584
  • 财政年份:
    2021
  • 资助金额:
    $ 56.49万
  • 项目类别:
Intracellular functions of APOL1 in the kidney
APOL1 在肾脏中的细胞内功能
  • 批准号:
    10252083
  • 财政年份:
    2020
  • 资助金额:
    $ 56.49万
  • 项目类别:
Mechanisms of APOL1-mediated kidney disease
APOL1 介导的肾脏疾病的机制
  • 批准号:
    9146894
  • 财政年份:
    2015
  • 资助金额:
    $ 56.49万
  • 项目类别:
Mechanisms of APOL1-mediated kidney disease
APOL1 介导的肾脏疾病的机制
  • 批准号:
    9319750
  • 财政年份:
    2015
  • 资助金额:
    $ 56.49万
  • 项目类别:
Kidney disease mechanisms associated with human genetic variation
与人类遗传变异相关的肾脏疾病机制
  • 批准号:
    9284462
  • 财政年份:
    2014
  • 资助金额:
    $ 56.49万
  • 项目类别:
Kidney disease mechanisms associated with human genetic variation
与人类遗传变异相关的肾脏疾病机制
  • 批准号:
    8642932
  • 财政年份:
    2014
  • 资助金额:
    $ 56.49万
  • 项目类别:
Kidney disease mechanisms associated with human genetic variation
与人类遗传变异相关的肾脏疾病机制
  • 批准号:
    9653298
  • 财政年份:
    2014
  • 资助金额:
    $ 56.49万
  • 项目类别:
Cell junction proteins in podocyte injury repair
足细胞损伤修复中的细胞连接蛋白
  • 批准号:
    8342329
  • 财政年份:
    2012
  • 资助金额:
    $ 56.49万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 56.49万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 56.49万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 56.49万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 56.49万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 56.49万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 56.49万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 56.49万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 56.49万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 56.49万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 56.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了